Eric Lefkofsky’s Tempus Continues Growth

Posted on

Billionaire Eric Lefkofsky’s new company Tempus has gained around $80 million in new funding from its investors. The Chicago-based Tempus was founded as a startup in 2015 as a technology-based company that helps personalize cancer treatment based on data. The latest investments bringing the total since the company was founded to around $210 million. This makes the company worth in excess of $1.1 billion.

Tempus currently has just a over 400 employees in the Chicago area and has been increasing at a rate of around 30 each month. Eric Lefkofsky plans for that pace to continue as Tempus attempts to grow its reach across the U.S. and the world. The value and size of the company means that it has now achieved “unicorn” status, something that not many startups have the distinction of having.

Tempus uses data in order to customized treatment plans for cancer patients in hopes of making the treatments more effective and efficient. The clinical and molecular data is collected and used to find potential trends in cancer treatment as well as help doctors and patients communicate more effectively.

Eric Lefkofsky is proud of the company and the relationships its has in the health car industry, from doctors to pharmaceutical companies. He says that the data side of his business and how it can help enhance cancer treatment is shifting the way in which cancer treatment is being seen among those in the healthcare community.

The $80 million investment in Tempus came from many individuals and companies to include previous investors, New Enterprise Associates and Revolution Growth. New investors in Tempus include T. Rowe Price Associates funds and the Kinship Trust Company. The new and existing investors will help Tempus grow their operations and help them reach more doctors and patients. This increase in data will further help the company find more innovative solutions for the treatment of cancers.

To Know More Click Here